Business Wire

1. Iambic Launches Enchant v3 – Molecular Superintelligence Designed To Advance End-To-End Drug Discovery & Development 9/21/2026

   Iambic, a clinical-stage life science and technology company developing novel medicines using its AI-driven platform, today unveiled Enchant v3, the next generation of its multimodal transformer model built to advance end-to-end drug discovery and development.

2. Niagen Bioscience Engages Veteran Pharmaceutical Executives And Biotechnology Experts To Support Drug Development Program And Strategic Business Growth 9/17/2026

   Niagen Bioscience, Inc., the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, announces today that its wholly owned subsidiary, NAD Pharmaceuticals Corp., has engaged Red Sky Partners, a life sciences strategic advisory firm, to support the advancement of NB4168, the Company’s small molecule investigational drug candidate, targeting rare genetic diseases and aging-related disorders.

3. Twist Bioscience Joins Lilly Tunelab To Advance Antibody Drug Discovery 9/16/2026

   Twist Bioscience Corporation, a mid-cap growth and value biotech company, today announced an agreement with Lilly TuneLab, a collaborative AI/ML drug discovery platform created by Eli Lilly and Company (Lilly).

4. Emulate Enters Final Stage Of FDA ISTAND Program For Human Liver-Chip With Submission Of Qualification Package Covering Both Zoë And AVA Organ-Chip Platforms 9/9/2026

   Emulate, Inc., the leading provider of next-generation Organ-on-a-Chip technology, today announced it has submitted its FDA Innovative Science and Technology Approaches for New Drugs (ISTAND) full qualification package (FQP) for its Human Liver-Chip, advancing the company's efforts to establish Organ-on-a-Chip technology as a qualified Drug Development Tool (DDT) for drug-induced liver injury (DILI) assessment.

5. Revvity To Acquire Human Cell Design To Advance Human-Relevant Cell Models For Metabolic Disease Drug Discovery 9/9/2026

   Revvity, Inc. today announced it has entered into a definitive agreement to acquire Human Cell Design (HCD), a France-based biotechnology company specializing in human cell models and preclinical research solutions for diabetes, obesity and other metabolic diseases.

6. BenchSci Announces Two-Year Enterprise Agreement With Argenx To Advance AI-Driven Preclinical Drug Discovery 9/2/2026

   BenchSci, a leading provider of AI software for biopharma research and development, today announced a two-year enterprise agreement with argenx, a global immunology innovation company, to deploy EMET, BenchSci's agentic research environment for preclinical drug discovery, within the organization.

7. Biocytogen Enters Into Non-Exclusive Licensing Agreement With Qilu Pharmaceutical For A Fully Human VHH Antibody To Support Innovative Drug Development In Neuroscience 9/2/2026

   Biocytogen Pharmaceuticals (Beijing) Co., Ltd. today announced that it has entered into a non-exclusive licensing agreement with Qilu Pharmaceutical Co., Ltd. (“Qilu Pharmaceutical”) for a fully human VHH antibody molecule.

8. Weave Bio Announces Collaboration With Takeda To Deploy AI-Native Regulatory Automation Across Key Drug Development Activities 9/1/2026

   Weave Bio, the leader in AI-native regulatory automation for drug development, today announced a collaboration with Takeda to deploy the Weave platform across 14 active programs in multiple global markets.

9. FluoSphera Licenses Debiopharm's AbYlink Technology For 3D Antibody Characterization While Leveraging Leica Microsystems Viventis Deep Imaging Capabilities 9/1/2026

   Debiopharm (Debiopharm Research & Manufacturing), a privately-owned, Swiss-based biopharmaceutical company aiming to establish tomorrow’s standard of care to cure cancer and infectious diseases and FluoSphera, a Swiss biotechnology company developing advanced in vitro platforms to improve the prediction of drug efficacy and safety, today announced a new license agreement for use of AbYlink, Debiopharm’s proprietary antibody conjugation technology.

10. Artis BioSolutions Launches mRNA And Lipid Nanoparticle Manufacturing Capabilities At New 'Genetic Medicines Center Of Excellence' In Bilbao, Spain 8/26/2026

    Artis BioSolutions, a company founded to streamline the discovery, development, and production of genetic medicines, today announced the launch of its Genetic Medicines Center of Excellence in Bilbao, Spain.